Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H17I4NO4 |
Molecular Weight | 818.9498 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C(C)(N)CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1
InChI
InChIKey=LWZCMKGGFONJPB-UHFFFAOYSA-N
InChI=1S/C18H17I4NO4/c1-3-26-17(25)18(2,23)8-9-4-13(21)16(14(22)5-9)27-10-6-11(19)15(24)12(20)7-10/h4-7,24H,3,8,23H2,1-2H3
Molecular Formula | C18H17I4NO4 |
Molecular Weight | 818.9498 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Etiroxate is a synthetic thyroxine derivative. It was used for the treatment of patients with hyperlipoproteinaemia. There were only slight side effects, such as gastric and autonomic nervous system symptoms. No statistically significant increase in anginal symptoms was found, even in patients with known coronary insufficiency. No negative effects on hepatic and renal function or the peripheral blood count were observed. Etiroxate caused a significant reduction in serum cholesterol, LDL-cholesterol, and serum apolipoprotein B. There was a significant decrease in HDL-cholesterol. Etiroxate might be used for the treatment and prevention of atherosclerotic disease.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7247989
40 mg daily
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:20:21 GMT 2023
by
admin
on
Fri Dec 15 16:20:21 GMT 2023
|
Record UNII |
0S3LDN5P7H
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1553
Created by
admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000082098
Created by
admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
|
PRIMARY | |||
|
65683
Created by
admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
|
PRIMARY | |||
|
C010150
Created by
admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104225
Created by
admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
|
PRIMARY | |||
|
m1142
Created by
admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
|
PRIMARY | Merck Index | ||
|
C65580
Created by
admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
|
PRIMARY | |||
|
0S3LDN5P7H
Created by
admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
|
PRIMARY | |||
|
DTXSID30864773
Created by
admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
|
PRIMARY | |||
|
SUB07309MIG
Created by
admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
|
PRIMARY | |||
|
3210
Created by
admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
|
PRIMARY | |||
|
17365-01-4
Created by
admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
|
PRIMARY | |||
|
3603
Created by
admin on Fri Dec 15 16:20:21 GMT 2023 , Edited by admin on Fri Dec 15 16:20:21 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |